EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Belite Bio's enterprise value is $1,270.46 Mil.
Belite Bio's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was $-33.05 Mil. Therefore, Belite Bio's EV-to-EBITDA for today is -38.45.
The historical rank and industry rank for Belite Bio's EV-to-EBITDA or its related term are showing as below:
BLTE'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -114.09 Med: 0 Max: 0
Current: -38.45
BLTE's EV-to-EBITDA is ranked worse than 100% of 451
companies
in the Biotechnology industry
Industry Median: 9.67
vs BLTE: -38.45
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-05-27), Belite Bio's stock price is $45.57.
Belite Bio's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-1.174. Therefore, Belite Bio's PE Ratio for today is At Loss.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
Belite Bio EV-to-EBITDA Historical Data
The historical data trend for Belite Bio's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Belite Bio's EV-to-EBITDA
For the Biotechnology subindustry, Belite Bio's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Belite Bio's EV-to-EBITDA Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Belite Bio's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Belite Bio's EV-to-EBITDA falls into.
Belite Bio EV-to-EBITDA Calculation
Belite Bio's EV-to-EBITDA for today is calculated as:
Belite Bio's current Enterprise Value is $1,270.46 Mil.
Belite Bio's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-33.05 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Belite Bio (NAS:BLTE) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Belite Bio's share price for today is $45.57.
Belite Bio's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.174.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of Belite Bio's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively lead to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
BLTE has been successfully added to your 